CO5170501A1 - AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO - Google Patents

AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO

Info

Publication number
CO5170501A1
CO5170501A1 CO00026470A CO00026470A CO5170501A1 CO 5170501 A1 CO5170501 A1 CO 5170501A1 CO 00026470 A CO00026470 A CO 00026470A CO 00026470 A CO00026470 A CO 00026470A CO 5170501 A1 CO5170501 A1 CO 5170501A1
Authority
CO
Colombia
Prior art keywords
carbon atoms
alkyl
halogen
optionally substituted
atoms
Prior art date
Application number
CO00026470A
Other languages
English (en)
Inventor
Revesz Laszlo
Achim Schlapbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9908531.8A external-priority patent/GB9908531D0/en
Priority claimed from GBGB9908532.6A external-priority patent/GB9908532D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5170501A1 publication Critical patent/CO5170501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención se relaciona con un compuesto de la fórmula I :<EMI FILE="00026470_1" ID="1" IMF=JPEG >en donde: a es N o C;b es CH cuando a es N, u O cuando a es C;--- denota un enlace sencillo o doble, dependiendo de si el anillo de azol es un anillo de imidazol o de oxazol;Z es N o CH;W es -NR6-Y-, -O-, ó -S-,en donde R6 es H, alquilo de 1 a 4 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono-alquilo de 1 a 3 átomos de carbono, arilo de 6 a 18 átomos de carbono, heteroarilo de 3 a 18 átomos de carbono, aralquilo de 7 a 19 átomos de carbono, o heteroaralquilo de 4 a 19 átomos de carbono, e - Y - es alquileno de 1 a 4 átomos de carbono, o un enlace directo;R2 es fenilo, opcionalmente sustituido por uno o más sustituyentes, cada uno de los cuales se selecciona independientemente a partir de halógeno, CF3, ciano, amido, o tioamido, carboxilato o tiocarboxilato, alcoxilo de 1 a 4 átomos de carbono, alquilo de 1 a 4 átomos de carbono, o NH2 que está opcionalmente sustituido por mono- o di-N-alquilo de 1 a 4 átomos de carbono;R3 es H, halógeno, alquilo de 1 a 10 átomos de carbono, cicloalquilo de 3 a 10 átomos de carbono, heterocicloalquilo de 3 a 18 átomos de carbono, arilo de 6 a 18 átomos de carbono, heteroarilo de 3 a 18 átomos de carbono, o metilenaminoguanidinilo (es decir, -CH=N-NH-C(NH).NH2), cada uno de los cuales está opcionalmente sustituido por hasta cuatro sustituyentes seleccionados por separado a partir de alquilo de 1 a 4 átomos de carbono, halógeno, alquilo de 1 a 4 átomos de carbono sustituido por halógeno, hidroxilo, alcoxilo de 1 a 4 átomos de carbono, tioalquilo de 1 a 4 átomos de carbono, o amino opcionalmente sustituido por mono- o di-N-alquilo de 1 a 4 átomos de carbono, o por N-heterociclilo que contiene de 5 a 7 átomos del anillo, y que contiene opcionalmente un heteroátomo adicional;R5 es arilo de 6 a 18 átomos de carbono, heteroarilo de 3 a 18 átomos de carbono, o cicloalquilo de 3 a 12 átomos de carbono, cada uno de los cuales está opcionalmente sustituido por hasta cuatro sustituyentes seleccionados por separado a partir de alquilo de 1 a 4 átomos de carbono, halógeno, alquilo de 1 a 4 átomos de carbono sustituido por halógeno, hidroxilo, alcoxilo de 1 a 4 átomos de carbono, tioalquilo de 1 a 4 átomos de carbono, o amino opcionalmente sustituido por mono- o di-N-alquilo de 1 a 4 átomos de carbono, o por N-heterociclilo que contiene de 5 a 7 átomos del anillo, y que opcionalmente contiene un heteroátomo adicional, o un ésteres del mismo y sales de adición de ácido del mismo. Igualmente, se refiere a una composición farmacéutica que contiene dicho compuesto y el proceso para la preparación del mismo.
CO00026470A 1999-04-14 2000-04-11 AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO CO5170501A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9908531.8A GB9908531D0 (en) 1999-04-14 1999-04-14 Organic compounds
GBGB9908532.6A GB9908532D0 (en) 1999-04-14 1999-04-14 Organic compounds

Publications (1)

Publication Number Publication Date
CO5170501A1 true CO5170501A1 (es) 2002-06-27

Family

ID=26315413

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00026470A CO5170501A1 (es) 1999-04-14 2000-04-11 AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO

Country Status (25)

Country Link
US (1) US6579874B2 (es)
EP (1) EP1224180B1 (es)
JP (1) JP2003503311A (es)
KR (1) KR20010108504A (es)
CN (1) CN1378544A (es)
AR (1) AR023465A1 (es)
AT (1) ATE244236T1 (es)
AU (1) AU4295300A (es)
BR (1) BR0010598A (es)
CA (1) CA2370417A1 (es)
CO (1) CO5170501A1 (es)
CZ (1) CZ20013696A3 (es)
DE (1) DE60003709T2 (es)
DK (1) DK1224180T3 (es)
ES (1) ES2202114T3 (es)
HU (1) HUP0302747A2 (es)
IL (1) IL145836A0 (es)
MX (1) MXPA01010434A (es)
NO (1) NO20014987L (es)
PE (1) PE20010031A1 (es)
PL (1) PL364789A1 (es)
PT (1) PT1224180E (es)
SK (1) SK14562001A3 (es)
TR (1) TR200102967T2 (es)
WO (1) WO2000063204A2 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511378A (ja) 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
EP1224185B1 (en) * 1999-10-27 2005-11-30 Novartis AG Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
ATE430742T1 (de) 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
CA2436739A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
CA2437248A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
BR0207957A (pt) * 2001-03-09 2004-02-25 Pfizer Prod Inc Compostos antiinflamatórios de benzimidazol
AP2002002463A0 (en) 2001-03-09 2002-06-30 Pfizer Prod Inc Novel triazolo-pyrimides anti-inflammatory compounds.
DE60205974T2 (de) 2001-04-04 2006-06-29 Pfizer Products Inc., Groton Neue Benzotriazole mit entzündungshemmender Wirkung
WO2002100433A1 (en) * 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Medicinal compositions
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
US7109216B2 (en) 2001-09-21 2006-09-19 Solvay Pharmaceuticals B.V. 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
CA2456606C (en) 2001-09-21 2010-01-26 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
US7473695B2 (en) * 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
WO2003053922A2 (en) * 2001-12-19 2003-07-03 Merck & Co., Inc. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1534282B1 (en) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
EP1529045A2 (en) 2002-08-09 2005-05-11 Astra Zeneca AB New compounds
JP2006502134A (ja) 2002-08-09 2006-01-19 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体において活性を有する化合物
KR20050039846A (ko) * 2002-08-09 2005-04-29 아스트라제네카 에이비이 메타보트로픽 글루타메이트 수용체-5의 조절제로서의옥사디아졸
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
JP2006508914A (ja) * 2002-08-30 2006-03-16 ファイザー・プロダクツ・インク トリアゾロ−ピリジン製造のための新規な方法および中間体
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
ATE478859T1 (de) 2003-02-07 2010-09-15 Daiichi Sankyo Co Ltd Pyrazolderivat
WO2004072072A1 (en) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
MY143245A (en) * 2004-04-28 2011-04-15 Mitsubishi Tanabe Pharma Corp 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
JP4803034B2 (ja) 2004-06-30 2011-10-26 Ｍｓｄ株式会社 ビアリール誘導体
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1988825B1 (en) * 2006-02-08 2016-12-21 The General Hospital Corporation Arrangements and systems for obtaining information associated with an anatomical sample using optical microscopy
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
MX2009011754A (es) * 2007-04-30 2009-12-01 Abbott Lab Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
RU2011151603A (ru) * 2009-05-19 2013-06-27 ДАУ АГРОСАЙЕНСИЗ ЭлЭсСи Соединения и способы борьбы с грибами
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
MA34797B1 (fr) 2010-08-11 2014-01-02 Millennium Pharm Inc Hétéroaryles et leurs utilisations
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2627181A4 (en) 2010-10-13 2014-03-19 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
AR086113A1 (es) 2011-04-30 2013-11-20 Abbott Lab Isoxazolinas como agentes terapeuticos
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
JPWO2018159650A1 (ja) * 2017-02-28 2019-12-19 東レ株式会社 グアニジン誘導体及びその医薬用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69433501T2 (de) * 1993-11-08 2004-11-04 Smithkline Beecham Corp. Oxazole zur behandlung von zytokinvermittelten erkrankungen
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
JP3294616B2 (ja) * 1995-08-10 2002-06-24 メルク エンド カンパニー インコーポレーテッド ２−置換アリールピロール、このような化合物を含む組成物及び使用方法
US6492516B1 (en) * 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity

Also Published As

Publication number Publication date
BR0010598A (pt) 2002-02-05
US20020049220A1 (en) 2002-04-25
DK1224180T3 (da) 2003-10-20
PL364789A1 (en) 2004-12-13
CZ20013696A3 (cs) 2002-02-13
EP1224180A2 (en) 2002-07-24
MXPA01010434A (es) 2002-03-27
CN1378544A (zh) 2002-11-06
NO20014987L (no) 2001-12-14
SK14562001A3 (sk) 2002-03-05
DE60003709D1 (de) 2003-08-07
EP1224180B1 (en) 2003-07-02
NO20014987D0 (no) 2001-10-12
WO2000063204A3 (en) 2002-05-23
CA2370417A1 (en) 2000-10-26
ATE244236T1 (de) 2003-07-15
PT1224180E (pt) 2003-11-28
AR023465A1 (es) 2002-09-04
IL145836A0 (en) 2002-07-25
JP2003503311A (ja) 2003-01-28
ES2202114T3 (es) 2004-04-01
KR20010108504A (ko) 2001-12-07
DE60003709T2 (de) 2004-12-23
HUP0302747A2 (hu) 2003-12-29
AU4295300A (en) 2000-11-02
PE20010031A1 (es) 2001-02-23
WO2000063204A2 (en) 2000-10-26
TR200102967T2 (tr) 2002-01-21
US6579874B2 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
CO5170501A1 (es) AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
RU2361870C2 (ru) Новые кумарины, их карбоксамидные производные, способы получения, композиции и применение
IL172993A0 (en) Thiazolo-,oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases
CO5261612A1 (es) Inhibidores de girasa y usos de esta
RU2403250C2 (ru) Производные пиперидин-4-иламида и их применение в качестве антагонистов рецептора sst подтипа 5
KR890008126A (ko) 피리다진아민 유도체
RU2005127052A (ru) Соединения тиенопиримидина и их применение
CO5251463A1 (es) Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos
CA2223237A1 (en) 1-phenyl-pyrazole derivatives and their use as parasiticidal agents
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
EA200101194A1 (ru) Производные 4,5,6,7-тетрагидроиндазола в качестве противоопухолевых средств
UA42669A (uk) Антагоністи ангіотензину ii, спосіб їх отримання (варіанти), проміжна сполука (варіанти), спосіб їх отримання та фармацевтична композиція
DK0528337T3 (da) Thiazolylbenzofuranderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater, der indeholder disse forbin
CO5200785A1 (es) Uso terapeutico de quinazolina
PE20090297A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis
AR047329A1 (es) Derivados de quinolinas para el tratamiento de enfermedades cardiovasculares. composiciones farmaceuticas
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
RU2007147344A (ru) Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний
TW200519088A (en) Aryl or heteroaryl amide compounds
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20030702A1 (es) Inhibidores de pde9 para tratamiento de transtornos cardiovasculares
RU2007147346A (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
CA2617991A1 (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
RU2006130002A (ru) ПРОИЗВОДНЫЕ ТРИАЗОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ А2b

Legal Events

Date Code Title Description
FC Application refused